Biomarkers including HRR mutations, PTEN loss, and PSMA expression can guide triplet selection in mHSPC, according to Benjamin Garmezy, MD.
|Poll|August 22, 2019
Poll: Is DRE still a relevant tool in the management of prostate cancer?
Do you feel that DRE is still a relevant tool in the management of prostate cancer? Take our latest poll and let us know.
Advertisement
Advertisement
Related to this article
Alicia Morgans, MD, discusses ARACOG findings on cognitive outcomes with darolutamide vs enzalutamide and the influence of genetic dementia risk.
Aaron Berger, MD, discusses patient selection for ARPI treatment holidays, monitoring during interruptions, and the role of testosterone recovery in interpreting PSA kinetics.
Tamim Niazi, MDCM, reviews DASL-HiCaP findings showing improved metastasis-free survival with darolutamide added to ADT and radiation therapy.
Chad Ritch, MD, discusses differences between PSMA-PET imaging agents and the need for further evidence to guide clinical decision-making.
Chad Ritch, MD, discusses how PSMA-PET informs patient management across different stages of the prostate cancer journey.
Alicia K. Morgans, MD, MPH, reviews promising prostate cancer findings from ESMO 2026,
Topline results from the study are anticipated in the first half of 2027.
Advertisement
Advertisement
Trending on Urology Times
1
Treating MIBC as a systemic disease reshapes bladder preservation
2
Alicia Morgans, MD, discusses cognitive outcomes with darolutamide vs enzalutamide
3
Durvalumab plus BCG may best serve patients with high-grade T1 NMIBC
4
William Huang, MD, discusses the potential of histotripsy for renal tumors
5